基于硼替佐米治疗难治或复发性多发性骨髓瘤的临床观察  

Clinical Observation of Bortezomib-Based Regimen for Treatment of Relapsed or Refractory Multiple Myeloma

作　　者：蒋英俊[1] 孔凡良[1] 缪华伟[1] 王凤云[1] 

机构地区：[1]安徽省合肥市第二人民医院血液肿瘤科,230011

出　　处：《中华全科医学》2013年第9期1355-1357,共3页Chinese Journal of General Practice

摘　　要：目的比较两种基于硼替佐米治疗难治性或复发性多发性骨髓瘤(MM)的方案临床疗效及不良反应,即硼替佐米联合环磷酰胺和地塞米松组(A组),以及硼替佐米联合环磷酰胺、地塞米松和沙利度胺组(B组)。方法 32例患者接受至少2个周期的A化疗方案;30例患者接受至少2个周期的B方案,即在A方案基础上联合使用沙利度胺。结果 A组和B组的治疗有效率分别为84.4%和86.7%(P>0.05)。两组血液学毒性不良反应发生率相似。在非血液学毒性不良反应,B组较A组具有较高的恶心、便秘、运动神经病变、感觉神经病变和头晕发生率(P<0.05)。结论 A方案与B方案相比在治疗复发性或难治性MM具有相似的治疗效果且具有较低的严重性非血液学毒性。Objective To compare the clinical responses and toxicities of two Bortezomib-based regimens for the treatment of relapsed or refractory multiple myeloma（MM）. Methods Thirty-two patients received at least two cycles of treatment with che- motherapeutic regimen A （Bortezomib-based salvage chemotherapy combined with CycIophosphamide and Dexamethasone ） , and thirty patients were given the regimen B （ Bortezomib combined with Cyclophosphamide, Dexamethasone and Thalidomide）. Re- suits The overall response rates of the group A and group B were 84.4% and 86.7% （ P 〉 0.05 ） ,respectively. Adverse hema- tologic events occurred in the same proportion of patients in both groups. In terms of non-hematologic toxicities, the group B showed a higher proportion of nausea, constipation, motor neuropathy, sensory neuropathy and dizziness compared to the group A （ each,P 〈 0.05 ）. Conclusion The regimen A for relapsed or refractory MM is an effective and more tolerable salvage therapy as compared to regimen B in terms of its comparable response rate and less severe of non-hematologic toxicities.

关 键 词：多发性骨髓瘤 硼替佐米 沙利度胺 非血液学毒性 

分 类 号：R733.3[医药卫生—肿瘤] R730.53[医药卫生—临床医学]